Piperazine-substituted benzothiophenes for treatment of mental disorders
USRE48059E1 · kind E1 · reissue
0Cited by
40References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 16, 2017 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | Nov 16, 2037 |
Classification
- Technology area (CPC —)General
Abstract
The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.